Release Details

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 26, 2007--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today additions to their senior management group in commercial and clinical operations, as well as other staff promotions within the Company. Robert J. Terifay was named Senior Vice President, Commercial, reporting to Leonard Schleifer, M.D., Ph.D, Regeneron's President and Chief Executive Officer. Alain Thibault, M.D., is Vice President, Clinical Sciences-Oncology, reporting to Peter Powchik, M.D., Senior Vice President of Clinical Development.

"These new management team members strengthen our commercial and clinical development groups and will assist us in our efforts to advance our three lead product candidates and build commercial operations," remarked Dr. Schleifer. "Both Bob and Alain have a wealth of experience in the pharmaceutical industry and have displayed great knowledge and capability in their practice areas. These additions and recent staff promotions will help us move forward toward our goal of being a fully-integrated biopharmaceutical company with products that address serious healthcare problems."

Mr. Terifay will implement Regeneron's commercialization strategy and lead sales, marketing, and customer services activities. Dr. Thibault, who recently joined the Company, is overseeing clinical development of the VEGF Trap in oncology and will have responsibility for future oncology product candidates.

Mr. Terifay joins Regeneron with over 20 years of experience in operational and marketing roles within the pharmaceutical industry. He most recently served as President and Chief Operating Officer of Arginox Pharmaceuticals. Previously, he was Senior Vice President, Business Operations, at Synta Pharmaceuticals Corp., Senior Vice President, Oncology Commercial, at Millennium Pharmaceuticals Inc., and Vice President, Marketing at COR Therapeutics, Inc. Mr. Terifay brings to Regeneron expertise in commercial strategy and positioning new products for market-entry in the pharmaceutical industry. He has played significant roles in the commercialization of products in oncology and cardiology, and he has spearheaded several collaborations with industry leaders. Mr. Terifay received a Bachelor of Science degree from the University of Notre Dame and a Master of Management degree form the J.L. Kellogg Graduate School of Business at Northwestern University.

Dr. Thibault joins the Company from GeminX, Inc., where he served as a Senior Director for Clinical Development. He has also held senior research positions at Johnson & Johnson Pharmaceutical Research &

Development, as well as Roche Laboratories. Dr. Thibault brings to Regeneron expertise in clinical development of oncology products. Prior to his work in the pharmaceutical industry, Dr. Thibault served as an Assistant Professor at the University of Virginia, as well as a Protocol Chairman at the Clinical Pharmacology Branch at the National Cancer Institute. He received his M.D. from the McGill University Faculty of Medicine.

    Regeneron also announced several promotions:

    --  Stuart Kolinski was promoted to Senior Vice President, General
        Counsel and Secretary. He has served as Regeneron's Vice
        President, General Counsel and Secretary since September 2000.

    --  Kremena Simitchieva was promoted to Vice President, Marketing.
        She joined Regeneron in 2004 from Merck & Co., Inc.

    --  Douglas McCorkle was promoted to Vice President, Controller
        and Assistant Treasurer. He has served as Regeneron's
        Controller since May 1998.

    About Regeneron Pharmaceuticals

Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of inflammatory diseases, eye diseases, and cancer and has preclinical programs in other diseases and disorders.

This news release discusses historical information and includes forward-looking statements about Regeneron and its products, programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of our drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize our drug candidates, competing drugs that are superior to our product candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement, including our agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or to terminate without any product success, risks associated with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2005 and Form 10-Q for the quarter ended September 30, 2006. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.

Additional information about Regeneron and recent news releases are available on Regeneron's worldwide web site at www.regeneron.com

    CONTACT: Regeneron Pharmaceuticals, Inc.
             Vice President, Investor Relations
             Charles Poole, 914-345-7640
             charles.poole@regeneron.com
             or
             Media Relations
             Kimberly Chen, 212-845-5634
             kchen@biosector2.com

    SOURCE: Regeneron Pharmaceuticals, Inc.